SCHEMBL5452955

SCHEMBL5452955

Cn1c(=O)n(Cc2ccccc2)c(=O)c2nc(-c3ccccc3)c(Cl)nc21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.65
HPGD P15428 2/20 0.65
GAA P10253 2/20 0.65
KDM4E B2RXH2 1/20 0.65
GLA P06280 1/20 0.65
MEN1 O00255 2/20 0.50
POLB P06746 2/20 0.50
KMT2A Q03164 2/20 0.50
CTDSP1 Q9GZU7 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
ADORA2B P29275 1/20 0.50
MAPT P10636 3/20 0.49
PKM P14618 1/20 0.49
HIF1A Q16665 1/20 0.49
THRB P10828 2/20 0.48
TP53 P04637 2/20 0.48
BRAF P15056 1/20 0.47
PIK3CG P48736 1/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5437131 0.91 ALDH1A1 (0.62) ALDH1A1HPGDGAAKDM4EGLA
SCHEMBL5440125 0.90 HPGD (0.65) ALDH1A1HPGDGAAKDM4EGLA
SCHEMBL5437071 0.87 ALDH1A1 (0.64) ALDH1A1HPGDGAAKDM4EGLA
SCHEMBL5452939 0.84 KDM4E (0.89) ALDH1A1HPGDGAAKDM4EGLA
SCHEMBL5446562 0.83 ALDH1A1 (0.62) ALDH1A1HPGDGAAKDM4EGLA
SCHEMBL5452709 0.83 ALDH1A1 (0.59) ALDH1A1HPGDGAAKDM4EGLA
SCHEMBL5435794 0.82 ALDH1A1 (0.58) ALDH1A1HPGDGAAKDM4EGLA
SCHEMBL5445092 0.81 ALDH1A1 (0.57) ALDH1A1HPGDGAAKDM4EGLA
SCHEMBL5442804 0.80 LMNA (0.56) ALDH1A1HPGDGAAKDM4EGLA
SCHEMBL5440062 0.80 KDM4E (0.64) ALDH1A1HPGDGAAKDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636232-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-03-22 EP claimed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 WO claimed
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2007-02-22 US disclosed
EP-1636232-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-03-22 EP disclosed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 WO disclosed
EP-1479682-A1 Immunosuppressive effects of pteridine derivatives 4 AZA Bioscience nv (BE) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives TPMT, FKBP5, RRP15 ALDH1A1 1767/4885HPGD 1339/4885GAA 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.